Just in time for the approval of Tebentafusp for HLA-A*02:01-positive patients with metastatic uveal melanoma, the ASCO guideline was up-dated, now recommending:
These recommendations replace recommendation 4.1 in the original guideline.
Recommendation 4.1.1
Previously untreated HLA-A*02:01-positive patients with metastatic uveal melanoma should be offered tebentafusp (Type: Evidence-based, benefits outweigh harms; Evidence quality: Moderate; Strength of recommendation: Strong).
Recommendation 4.1.2
For all patients with uveal melanoma other than those addressed by Recommendation 4.1.1, no recommendation for or against any specific systemic therapy may be made at this time. Patients should be offered or referred for enrollment in clinical trials where possible (Type: No recommendation; Evidence quality: Low; Strength of recommendation: Not applicable).
based on the following evidence:
Read the full update here:
https://ascopubs.org/doi/full/10.1200/JCO.22.00944
Further reading
Nathan P, Hassel JC, Rutkowski P, et al: Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med 385:1196-1206, 2021 |
Comments
Post a Comment